The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review

Código QR

The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review

Objective: Sodium glucose cotransporter 2 inhibitors (SGLT2-is) are antidiabetic drugs that improve glycemic control by limiting urinary glucose reuptake in the proximal tubule. SGLT2-is might suppress atherosclerotic processes and ameliorate the prognosis of patients with diabetes mellitus diagnose...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aurélie Pahud de Mortanges, Dante Salvador Jr., Markus Laimer, Taulant Muka, Matthias Wilhelm, Arjola Bano
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	atherosclerotic cardiovascular disease SGLT2-inhibitors subclinical atherosclerosis diabetes review Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/a3554c9245464d81943eb2087b792037
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Is cancer incidence modified by SGLT2 inhibitors?
por: Lev M. Berstein
Publicado: (2019)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes BC, et al.
Publicado: (2019)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
por: Liu S, et al.
Publicado: (2019)

Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model
por: Liu Y, et al.
Publicado: (2021)

Leptin and leptin receptor evaluation in atherosclerotic plaques in patients with type 2 diabetes mellitus
por: Diana A. Dimitrova, et al.
Publicado: (2021)

12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus
por: Perna S, et al.
Publicado: (2018)

Comparison analysis of childhood body mass index cut-offs in predicting adulthood carotid intima media thickness: Tehran lipid and glucose study
por: Farhad Hosseinpanah, et al.
Publicado: (2021)

Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
por: Steffen Pabel, et al.
Publicado: (2021)

Glucose and other hexoses transporters in marine invertebrates: A mini review
por: Martínez-Quintana,José Alfredo, et al.
Publicado: (2012)

ARYA atherosclerosis
Publicado: (2005)

Role of endothelial cell specific molecule-1 (endocan) and cardiac imaging in early detection of cardiac involvement in psoriatic patients with or without arthritis
por: Salwa M.A. Ibrahim, et al.
Publicado: (2022)

FMD and CIMT: Surrogate markers of atherosclerosis in subclinical and overt hypothyroidism in sub Himalyan Region
por: Bandana Kumari, et al.
Publicado: (2021)

Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages
por: Masao Koike, et al.
Publicado: (2021)

Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by Focusing on Fatty Acid Metabolism
por: Kawarasaki S, et al.
Publicado: (2020)

Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension
por: Silvie Hojná, et al.
Publicado: (2021)

Mizagliflozin, a selective SGLT1 inhibitor, improves vascular cognitive impairment in a mouse model of small vessel disease
por: Nanae Ishida, et al.
Publicado: (2021)

Canagliflozin review – safety and efficacy profile in patients with T2DM
por: Jakher H, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
por: Muhammad Afzal, et al.
Publicado: (2021)

Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials
por: Mei Qiu, et al.
Publicado: (2021)

Upregulation Of Renal GLUT2 And SGLT2 Is Involved In High-Fat Diet-Induced Gestational Diabetes In Mice
por: Jiang YK, et al.
Publicado: (2019)

Morphological Irregularity of Unruptured Intracranial Aneurysms is More Related with Aneurysm Size Rather Than Cerebrovascular Atherosclerosis: A Case-Control Study
por: Qi P, et al.
Publicado: (2021)

Empagliflozin in type 1 diabetes
por: Mathieu C, et al.
Publicado: (2019)

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
por: Ahmadieh H, et al.
Publicado: (2017)

Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
por: Jadwiga Nessler
Publicado: (2021)

The Interplay of Vitamin D Deficiency and Cellular Senescence in The Pathogenesis of Obesity-Related Co-Morbidities
por: Abdulhadi Bima, et al.
Publicado: (2021)

Journal Club: What Are the Implications of the Presence of Magnetic Resonance Imaging–Detected Erosions and Synovitis in Healthy People?
por: Rayan Najjar
Publicado: (2021)

Subclinical Atherosclerosis Progression in Obese Children with Relevant Cardiometabolic Risk Factors Can Be Assessed through Carotid Intima Media Thickness
por: Monica-Simina Mihuta, et al.
Publicado: (2021)

Atherosclerosis.
Publicado: (2000)

STUDYING OF APPLICATION IMMUNOMODULATOR «GALAVIT» AT EXPERIMENTAL ATHEROSCLEROSIS
por: E. P. Turmova, et al.
Publicado: (2012)

Scavenger Receptors and Atherosclerosis
por: RIGOTTI,ATTILIO
Publicado: (2000)

Empagliflozin: a new strategy for nephroprotection in diabetes
por: Anton Ivanovich Korbut, et al.
Publicado: (2017)

Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
por: Olga Yuryevna Sukhareva, et al.
Publicado: (2016)

Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
por: Yu H, et al.
Publicado: (2017)

Relationship between β-hydroxybutyrate and the fat: protein ratio of milk during early lactation in dairy cows
por: García,CAC, et al.
Publicado: (2015)

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
por: Seko Y, et al.
Publicado: (2018)

A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
por: Shen L, et al.
Publicado: (2021)

Second line therapy in type 2 diabetes: legacy effect activation
por: Ekaterina A. Shestakova
Publicado: (2017)

Nanotechnology for Targeted Therapy of Atherosclerosis
por: Seyedmehdi Hossaini Nasr, et al.
Publicado: (2021)

Involvement of Intestinal Goblet Cells and Changes in Sodium Glucose Transporters Expression: Possible Therapeutic Targets in Autistic BTBR T<sup>+</sup>Itpr3<sup>tf</sup>/J Mice
por: Caterina Franco, et al.
Publicado: (2021)

Characterisation of Staphylococcus aureus isolated from cases of bovine subclinical mastitis in two Uruguayan dairy farms
por: de los Santos,R, et al.
Publicado: (2014)